| 000 | 01655 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517163055.0 | ||
| 264 | 0 | _c20180430 | |
| 008 | 201804s 0 0 eng d | ||
| 022 | _a2567-689X | ||
| 024 | 7 |
_a10.1160/TH17-02-0129 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSchmidt, David E | |
| 245 | 0 | 0 |
_aWhole blood ristocetin-activated platelet impedance aggregometry (Multiplate) for the rapid detection of Von Willebrand disease. _h[electronic resource] |
| 260 |
_bThrombosis and haemostasis _c07 2017 |
||
| 300 |
_a1528-1533 p. _bdigital |
||
| 500 | _aPublication Type: Evaluation Study; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 | _aCase-Control Studies |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPlatelet Aggregation |
| 650 | 0 | 4 | _aPlatelet Function Tests |
| 650 | 0 | 4 | _aPoint-of-Care Testing |
| 650 | 0 | 4 | _aPredictive Value of Tests |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aROC Curve |
| 650 | 0 | 4 | _aReproducibility of Results |
| 650 | 0 | 4 |
_aRistocetin _xpharmacology |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aWorkflow |
| 650 | 0 | 4 |
_avon Willebrand Disease, Type 1 _xblood |
| 650 | 0 | 4 |
_avon Willebrand Disease, Type 2 _xblood |
| 650 | 0 | 4 |
_avon Willebrand Disease, Type 3 _xblood |
| 700 | 1 | _aBruzelius, Maria | |
| 700 | 1 | _aMajeed, Ammar | |
| 700 | 1 | _aOdeberg, Jacob | |
| 700 | 1 | _aHolmström, Margareta | |
| 700 | 1 | _aÅgren, Anna | |
| 773 | 0 |
_tThrombosis and haemostasis _gvol. 117 _gno. 8 _gp. 1528-1533 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1160/TH17-02-0129 _zAvailable from publisher's website |
| 999 |
_c27352617 _d27352617 |
||